Get the Stockscreener App
0.9651
11.53%
0.0998
After Hours:
.96
-0.0051
-0.53%
Renovorx Inc stock is traded at $0.9651, with a volume of 867.68K.
It is up +11.53% in the last 24 hours and up +2.27% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$0.8653
Open:
$0.9
24h Volume:
867.68K
Relative Volume:
3.27
Market Cap:
$43.53M
Revenue:
$1.49M
Net Income/Loss:
$-12.27M
P/E Ratio:
-2.9104
EPS:
-0.3316
Net Cash Flow:
$-11.30M
1W Performance:
+11.74%
1M Performance:
+2.27%
6M Performance:
+7.34%
1Y Performance:
-24.01%
1-Day Range:
$0.871
$0.98
1-Week Range:
$0.8401
$0.98
52-Week Range:
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.9651 | 39.02M | 1.49M | -12.27M | -11.30M | -0.3316 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Renovorx Inc Stock (RNXT) Latest News
RenovoRx Inc (RNXT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RenovoRx Inc (RNXT) Income Statement - TradingKey
RNXT|RenovoRx Inc|Price:0.959|Chg%:+0.093 - TradingKey
RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RenovoRx Inc (RNXT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RenovoRx Inc (RNXT) Balance Sheet - TradingKey
RenovoRx Inc (RNXT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RenovoRx Market Sentiment - Benzinga España
RenovoRx, Inc. Revenue Breakdown – NASDAQ:RNXT - TradingView
RenovoRx Inc (RNXT) Cash Flow - TradingKey
RNXT|RenovoRx Inc|Price:0.865|Chg%:+0.011 - TradingKey
A grandfather struggled with treatment for late-stage pancreatic cancer — until a clinical trial helped him beat the odds - CBS News
RenovoRx Inc (RNXT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RenovoRx, Inc. (RNXT) reports Q1 loss, tops revenue estimates - MSN
RenovoRx Inc. (RNXT) Q1 2026 Earnings: Wider-than-Expected Loss as Clinical Progress Remains Key FocusHigh Estimate Range - DonanımHaber
Frontier tech research, news & data - MLQ.ai
RNXTRenovoRx Inc Latest SEC Filings - Finviz
RenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk - The Globe and Mail
RenovoRx Receives Nasdaq Delisting Notice: Key Details from Latest 8-K Filing - Minichart
RenovoRx Received Notice of Noncompliance - TradingView
RenovoRx Stockholders Approve Directors and Equity Plan - The Globe and Mail
Nasdaq grants RenovoRx (RNXT) new deadline to fix $1 bid price - Stock Titan
RenovoRx, Inc. Financial Disclosures & SEC Filings - TradingView
RenovoRx 2021 Omnibus Equity Incentive Plan Amended: Key Vote Results and SEC Filing Details (June 2026) - Minichart
RenovoRx (RNXT) investors approve directors, expand equity plan and ratify 2026 auditor - Stock Titan
RenovoRx (RNXT) Edges Higher, Testing Key Resistance at $1.02Stock Buy Zone - dars.gov.et
RenovoRx Q1 2026 Earnings: EPS Misses Estimates as Clinical Pipeline Progress Takes Center StageProfit Inflection Point - dars.gov.et
Enterprise value to revenue forward of RenovoRx, Inc. – NASDAQ:RNXT - TradingView
Enterprise value to EBITDA forward of RenovoRx, Inc. – NASDAQ:RNXT - TradingView
Price to book forward of RenovoRx, Inc. – NASDAQ:RNXT - TradingView
RNXT Forecast — Price Target — Prediction for 2027 - TradingView
RenovoRx Inc (RNXT) Valuation: PE, PB & Fair Value Analysis - TradingKey
RenovoRx, Inc. Actuals & Estimates (NASDAQ:RNXT) - TradingView
RenovoRx (RNXT) Holds Near Support as Micro-Cap Biotech Shows Modest UptickLiquidity Order Flow - dars.gov.et
Form 4 RenovoRx Inc For: 24 June By Investing.com - Investing.com Nigeria
RenovoRx (RNXT) director reorganizes indirect share holdings via trust - Stock Titan
RNXT: Strong commercial growth and clinical data position the therapy for major impact in cancer care - TradingView
RNXT: Strong commercial growth and clinical data position the platform for expanded cancer therapy adoption - TradingView
RenovoRx Inc (RNXT) Institutional Confidence - TradingKey
RenovoRx Inc (RNXT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RenovoRx Inc (RNXT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre‑Revenue Biotech Advances Clinical ProgramsAnalyst Consensus Shift - newsline.com
RNXT News | RENOVORX INC (NASDAQ:RNXT) - ChartMill
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP in Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer - The Manila Times
Targeted artery chemo saw 52% tumor activity drop in pancreatic cancer case - Stock Titan
RenovoRx study shows targeted intra-arterial ge... - Pluang
RenovoRx (RNXT) Q1 2026 Earnings: EPS Falls Short of Estimates as Pre-Revenue Biotech Advances Clinical PipelineGuidance Update - newsline.com
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Oncology Firm Advances Clinical PipelineEarnings Whisper Number - newsline.com
RenovoRx Inc. (RNXT) Holds Steady Near Support as Investors Eye ResistanceInstitutional Flow Picks - newsline.com
RNXT Q1 2026 Earnings: EPS Miss Widens Losses as Stock Declines 10.6%EPS Consistency Score - Bölüm Sonu Canavarı
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):